Glofitamab for diffuse large B cell lymphoma
- VernacularTitle:弥漫大B细胞淋巴瘤治疗新药格菲妥单抗
- Author:
Li ZHENG
1
;
Kaihua ZHANG
2
;
Xuelin SUN
3
Author Information
1. Dept. of Pharmacy，China Aerospace Science & Industry Corporation 731 Hospital，Beijing 100074，China
2. Dept. of Thoracic Surgery，China Aerospace Science & Industry Corporation 731 Hospital，Beijing 100074，China
3. Dept. of Pharmacy，Beijing Hospital，Beijing 100730，China
- Publication Type:Journal Article
- Keywords:
glofitamab;
diffuse large B cell lymphoma;
CD3/CD20 bispecific monoclonal antibody;
pharmacological effects
- From:
China Pharmacy
2023;34(24):3064-3067
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B cell lymphoma （DLBCL） is a malignant tumor derived from mature B cells. Currently， chemotherapy is still the main clinical treatment. However， some patients experience recurrence or refractory conditions after treatment. On June 15， 2023， the FDA approved the marketing of glofitamab， a CD3/CD20 bispecific monoclonal antibody， to provide the new treatment plan for patients with recurrent or refractory DLBCL after receiving 2-line or above systemic treatment. This article reviews pharmacological effects， clinical studies， safety， usage and dosage of glofitamab. Glofitamab mainly plays a therapeutic role in DLBCL by promoting the activation and proliferation of T cells，activating T cells to release tumor cell-killing proteins， and mediating the lysis of B cells. Clinical studies have shown that glofitamab has a better complete and objective response rate for recurrent or refractory DLBCL. Common adverse reactions caused by glofitamab include mild/moderate cytokine release syndrome， musculoskeletal pain， rash， fatigue， and so on，without significant drug interactions.
